Vascular Endothelial Growth Factor - Its Relation to Neovascular ization and Their Significance as Prognostic Factors in Renal Cell Carcinoma.
10.3349/ymj.2001.42.5.539
- Author:
Ki Hak SONG
1
;
Jisun SONG
;
Goo Bo JEONG
;
Jung Min KIM
;
Soon Hee JUNG
;
Jaemann SONG
Author Information
1. Department of Urology, Yonsei University Wonju College of Medicine, Wonju, Korea. jmsong@wonju.yonsei.ac.kr
- Publication Type:Original Article ; Research Support, Non-U.S. Gov't
- Keywords:
Renal cell carcinoma;
vascular endothelial growth factor;
microvessel density
- MeSH:
Adult;
Aged;
Carcinoma, Renal Cell/*blood supply/*metabolism;
Endothelial Growth Factors/*metabolism;
Female;
Human;
Kidney Neoplasms/*blood supply/*metabolism;
Lymphokines/*metabolism;
Male;
Middle Age;
Neovascularization, Pathologic/*pathology;
Prognosis
- From:Yonsei Medical Journal
2001;42(5):539-546
- CountryRepublic of Korea
- Language:English
-
Abstract:
Angiogenesis is a series of processes that include endothelial proliferation, migration and tube formation. Vascular endothelial growth factor (VEGF) is regarded as a potent mediator of angiogenesis, vascular permeability and tumor cell growth in renal cell carcinoma. This study was designed to evaluate the expression of VEGF and the microvessel count (MVC) and to determine their prediction efficacies for prognosis in renal cell carcinoma. The relationship between the expression of VEGF and MVC were evaluated immunohistochemically in 50 patients with renal cell carcinoma who received a radical nephrectomy at Wonju Christian Hospital between 1989 and 1997. Microvessels were identified by immunostaining endothelial cells for CD-31 antigen. The mean follow-up was 96 months (3 - 133 months). Overall 5-year survival rate was 71.5%. VEGF was expressed in the tumor cell cytoplasm. Of the 50 tumors, 23 (46%) were weak to strongly positive for VEGF but 27 (54%) were unreactive. The respective 5-year survival rates for patients with positive and negative expressions of VEGF were 70% and 73% (p > 0.05). The overall mean MVC was 13.4 in a 400x field. Mean MVCs were significantly higher in VEGF-positive tumors (17.6 +/- 12.1) than in VEGF-negative tumors (9.9 +/- 5.4), and the MVCs of the high vascular density group and the low ascular density groups were significantly different. The 5-year survival rates of patients with high vascular density and low vascular density were 59% and 86%. The median survival period for patients with MVCs higher than or equal to 10 vessels/field was 85 months, whereas for those with MVCs lower than 10 vessels/field the median survival time was 102 months. These results suggest that MVC may be a better prognostic factor in renal cell carcinoma than the expression of VEGF.
